Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-8371 · 1 trial · 5 indications
Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities
Incidence of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Escalating doses of CTX-8371 |
| Dose Expansion Cohort 2 | EXPERIMENTAL | Two CTX-8371 dose groups (3.0 mg/kg and 10.0 mg/kg) in three tumor type subgroups (NSCLC, TNBC, and HL) |
| Name | Type | Description |
|---|---|---|
| CTX-8371 | DRUG | Intravenous (IV) infusion every two weeks. |
Inclusion Criteria: 1. Age 18 years or older 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including 1. M...
Top 20 of 90 competitors
CTX-8371 is an investigational small molecule being studied for the treatment of advanced solid tumors and blood cancers, including non small cell lung cancer, triple negative breast cancer, Hodgkin lymphoma, head and neck squamous cell carcinoma, and malignant melanoma. It is not yet approved for any indication and remains in clinical development.
CTX-8371 targets PD-L1, a protein that tumors use to suppress immune responses. By binding to PD-L1, the drug is designed to interfere with this immune checkpoint pathway and allow the immune system to recognize and attack cancer cells. It is a small molecule therapeutic being developed in oncology.
CTX-8371 is being developed by Compass Therapeutics, Inc., a biopharmaceutical company whose common stock trades on the Nasdaq under the ticker symbol CMPX. The company is the sponsor of the ongoing clinical trial evaluating the drug in patients with advanced malignancies.
CTX-8371 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 trial is currently recruiting participants and is designed to evaluate the drug in patients with advanced malignancies.
CTX-8371 is being evaluated in one active clinical trial, NCT06150664, titled "A Phase 1 of CTX-8371 in Patients With Advanced Malignancies." The study is recruiting up to 85 participants across sites in the United States and includes patients with non small cell lung cancer, triple negative breast cancer, Hodgkin lymphoma, head and neck squamous cell carcinoma, and malignant melanoma.
Yes, the Phase 1 trial of CTX-8371 is biomarker selected, meaning enrollment is guided by specific biological markers. The study is a controlled, non randomized, open label trial that is currently recruiting participants aged 18 years and older, including both male and female patients with advanced malignancies.